Alternatives to VI Therapeutics

A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.

A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Computational platform using LLMs trained on biological and chemical data for drug discovery.

AI-driven platform for protein-level disease mapping and drug discovery.

AI-powered blood test for early cancer detection and subtyping.

Compressing biology to develop the next generation of therapies.

AI-powered insights platform for life sciences and biotech workflows.

Revolutionizing prenatal testing with non-invasive fetal DNA analysis from maternal blood.

Synthetic biology startup optimizing gene expression for food and biotech applications.

Cloud-based platform for reproducible computational research in life sciences.

Developing polymer-based nanoparticles for targeted gene therapy delivery.

Unleashing the power of genomics at scale for biological advances and human health.

Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.

AI-driven digital twin of embryo development for cell-based therapies.

Life sciences data platform for deep-phenotype multi-omics datasets.

Developing a semiconductor-based protein detector using nanopore sensing for advanced identification.

Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.

Developing novel therapeutics for rare genetic diseases.